Canopy Growth Corp. shares rallied on stronger-than-expected third-quarter revenue, as the company aired plans to focus on premium cannabis brands in Canada and growth in a line of drinks and CBD products in the U.S. market.
It’s also eyeing ways to cut costs and streamline its operations, with plans to reveal more details in the coming quarter.
Canopy Growth Corp.
CGC,
WEED,
shares jumped 16.2%, wiping out its losses for the year. With Wednesday’s gains, the stock is now up 2.8% for 2022.
On a conference call with analysts, CEO David Klein said the company is meeting demand for higher-end cannabis with THC content in the mid-20% range, higher than just six month ago.
“The flower business in Canada is fast-moving,” he said. “We need to stay on top of the evolution in the market.”
See now: Cannabis companies pivot to debt to raise capital as stock prices lag
The company said its third-quarter net loss narrowed to C$108.93 million ($85.8 million), or 28 cents a share, from a loss of C$904.38 million, or C$2.43 a share, in the year-ago period.
Revenue at the cannabis company fell to C$140.9 million from C$152.5 million a year ago.
Analysts expected Canopy Growth to lose 28 cents a share on revenue of C$135.9 million, according to a FactSet survey.
Growth in consumer products such as BioSteel drinks and Storz & Bickel vapes was offset by a decline in Canadian cannabis sales. The company said it maintained its No. 1 position in the premium flower market in Canada.
Cantor Fitzgerald analyst Pablo Zuanic said Canopy Growth beat his estimate for consumer product sales, but fell short of his projection for global cannabis revenue.
“Canopy Growth says it is implementing a host of initiatives to stabilize Canadian recreational market share [and] it continues to deliver on cost savings targets,” he said.
On the consumer products side, he noted a “hefty” ramp-up of the company’s BioSteel drinks as part of its push into CBD and consumer packaged goods products in the U.S.
Canopy Growth, which is controlled by spirits giant Constellation Brands
STZ,
has begun burning cash for the first time, he said.
See:Senate Democrats face two possible avenues for cannabis legislation
Its U.S. product offerings include a line of Martha Steward CBD products, which were sold in 21% more locations in the third quarter compared to the previous quarter.
CFRA analyst Garrett Nelson reiterated his hold rating on Canopy Growth and reduced his 12-month price target to C$10 a share from C$14 a share.
“While shares are up…we remain cautious, viewing the stock as a broken growth story,” he said. “Once again, management pledged to reduce operating expenditures and capital expenditures, saying that with a renewed sense of urgency, it is focused on achieving profitability in Canada.”
The company’s cash dropped by C$560 million to C$1.42 billion from the previous quarter and Nelson said he’s concerned that liquidity could become an issue in the coming quarters, absent the “unlikely” passage of federal cannabis legislation in the U.S.
Shares of Constellation Brands rose 0.9%.
Also Read:
undefined
This post was originally published on Market Watch
